Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 6/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24834486 | 0.88 | NLRP3 (0.50) | NLRP3THRBALOX15NPSR1CHRNA7 | |
| SCHEMBL24834532 | 0.88 | NLRP3 (0.45) | NLRP3THRBALOX15NPSR1CHRNA7 | |
| SCHEMBL30169678 | 0.88 | NLRP3 (0.50) | NLRP3THRBALOX15NPSR1CHRNA7 | |
| SCHEMBL24077194 | 0.81 | NLRP3 (0.47) | NLRP3THRBALOX15NPSR1CHRNA7 | |
| SCHEMBL24077155 | 0.80 | NLRP3 (0.47) | NLRP3THRBALOX15NPSR1CHRNA7 | |
| SCHEMBL24077168 | 0.79 | NLRP3 (0.51) | NLRP3THRBALOX15NPSR1CHRNA7 | |
| SCHEMBL24077401 | 0.79 | NLRP3 (0.54) | NLRP3THRBALOX15NPSR1CHRNA7 | |
| SCHEMBL24077157 | 0.79 | NLRP3 (0.45) | NLRP3THRBALOX15NPSR1CHRNA7 | |
| SCHEMBL24834837 | 0.78 | ALOX15 (0.60) | ALOX15TP53RAB9A | |
| SCHEMBL24077174 | 0.78 | NLRP3 (0.45) | NLRP3ALOX15NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023275230-A1 | 5-OXO-PYRIDO[2,3-D]PYRIDAZIN-6(5H)-YL ACETAMIDES | JANSSEN PHARMACEUTICA NV (BE) | 2023-01-05 | — | — | WO | disclosed |